EGFR-TKI获得性耐药后是否继续TKI治疗:来自IMPRESS研究的启示

Would Patients Continue TKI after Acquired DrugResistance on EGFR-TKI: Inspiration from The IMPRESS Study

1文献来源Mok TS,Wu YL,Nakagawa K,et al.Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor（EGFR）mutation-positive non-smallcell lung cancer（NSCLC）after progression on firstline Gefitinib：The phaseⅢ,randomised IMPRESS study[J].Ann Oncol,2014,25（4s）：Abstr LBA2_PR.2证据水平1b。3背景一线表皮生长因子受体（epidermal growth factor receptor,EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitor,TKI）对于大部分EGFR突变阳性的非小细胞肺癌（non-small cell lung cancer,NSCLC）患者疗效显著,但随后不可避免地获得性耐药,出现疾病进展。